Posted by Michael Wonder on 06 Jul 2016
Takeda receives European Commission approval of Adcetris (brentuximab vedotin) for consolidation treatment in post-transplant Hodgkin's lymphoma
6 July 2016 - Approval based on AETHERA Phase 3 data demonstrating 75 percent improvement in progression-free survival for patients treated with Adcetris as consolidation therapy immediately following autologous stem cell transplant.
Takeda Pharmaceutical Company Limited today announced that the European Commission has extended the current conditional marketing authorization of Adcetris (brentuximab vedotin) and approved Adcentris for the treatment of adult patients with CD30+ Hodgkin's lymphoma at increased risk of relapse or progression following autologous stem cell transplant
The decision follows a positive opinion from the CHMP on May 26, 2016.
